IgG κ light chain Inhibitors
IgG κ light chain inhibitors are a class of compounds that specifically target the κ (kappa) light chains of immunoglobulin G (IgG) antibodies. The κ light chain, along with its counterpart, the λ (lambda) light chain, plays an essential role in forming the antigen-binding fragment (Fab) of antibodies. This fragment is critical for recognizing and binding to specific antigens. The light chain contributes to the structural diversity and specificity of the antibody by creating a variable region that interacts with antigens. IgG κ light chain inhibitors aim to disrupt these functions by binding to key sites within the κ light chain, altering its ability to participate in antigen recognition or antibody conformation. This type of inhibition can provide insights into how the κ light chain influences the antibody's overall function and its role in immune system dynamics.
The design of IgG κ light chain inhibitors often involves precise targeting of regions within the κ light chain that are important for antigen binding or structural stability. These inhibitors may bind to either the variable region, which determines antigen specificity, or the constant region, which helps maintain the integrity of the light chain. The interaction between the inhibitor and the κ light chain typically involves non-covalent forces such as hydrogen bonds, hydrophobic interactions, or van der Waals forces, ensuring specificity and stability. Through inhibition of the κ light chain, researchers can explore the unique biological roles of κ-containing antibodies, including their structural properties and antigen-binding behaviors. By studying the effects of these inhibitors, scientists can better understand the molecular mechanisms underlying antibody diversity and the distinct roles of light chains in immunoglobulin function.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Cyclophosphamide | 50-18-0 | sc-361165 sc-361165A sc-361165B sc-361165C | 50 mg 100 mg 500 mg 1 g | $76.00 $143.00 $469.00 $775.00 | 18 | |
Cyclophosphamide may induce DNA crosslinking and strand breaks, leading to transcriptional repression of genes, including those responsible for the production of the IgG κ light chain. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $68.00 | 2 | |
Chloroquine can disrupt endosomal acidification, which is critical for antigen presentation pathways in B cells. This disruption can lead to a decrease in B cell activation and subsequent IgG κ light chain synthesis. | ||||||
Methotrexate | 59-05-2 | sc-3507 sc-3507A | 100 mg 500 mg | $92.00 $209.00 | 33 | |
Methotrexate competitively inhibits dihydrofolate reductase, resulting in a depletion of nucleotide precursors and a subsequent decrease in DNA replication and cell division, thereby downregulating IgG κ light chain expression. | ||||||
Azathioprine | 446-86-6 | sc-210853D sc-210853 sc-210853A sc-210853B sc-210853C | 500 mg 1 g 2 g 5 g 10 g | $199.00 $173.00 $342.00 $495.00 $690.00 | 1 | |
Azathioprine metabolites incorporate into DNA, causing strand breakage and mispairing, which may lead to apoptosis of B cells, subsequently reducing the synthesis of IgG κ light chains. | ||||||
Hydroxyurea | 127-07-1 | sc-29061 sc-29061A | 5 g 25 g | $76.00 $255.00 | 18 | |
Hydroxyurea's inhibition of ribonucleotide reductase can lead to a shortage of deoxyribonucleotides, stalling DNA synthesis and cell cycle progression in B cells, which may decrease IgG κ light chain expression. | ||||||
6-Mercaptopurine | 50-44-2 | sc-361087 sc-361087A | 50 mg 100 mg | $71.00 $102.00 | ||
By disrupting purine nucleotide synthesis and interconversion, mercaptopurine can lead to decreased proliferation and function of B cells, resulting in reduced synthesis of IgG κ light chains. | ||||||
Leflunomide | 75706-12-6 | sc-202209 sc-202209A | 10 mg 50 mg | $20.00 $81.00 | 5 | |
Leflunomide can inhibit dihydroorotate dehydrogenase, leading to a deficiency in pyrimidine synthesis, which is essential for DNA replication. This can cause a reduction in B cell proliferation and downregulate IgG κ light chain production. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Bortezomib targets and inhibits the proteasome, leading to the accumulation of proteins destined for degradation. This may trigger apoptosis in B cells, thus reducing IgG κ light chain synthesis. | ||||||
Lenalidomide | 191732-72-6 | sc-218656 sc-218656A sc-218656B | 10 mg 100 mg 1 g | $49.00 $367.00 $2030.00 | 18 | |
Lenalidomide can interrupt the homeostatic proliferation and survival signals in B cells, leading to their apoptosis or cell cycle arrest, which in turn would decrease the production of IgG κ light chains. | ||||||
Thalidomide | 50-35-1 | sc-201445 sc-201445A | 100 mg 500 mg | $109.00 $350.00 | 8 | |
Thalidomide can lead to the degradation of transcription factors that are crucial for the survival and function of B cells, thereby potentially decreasing the expression of IgG κ light chain genes. | ||||||